A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas.
Xing Zhang(Sun Yat-sen University), Yifan Zhai(Unknown), Dajun Yang, Wenqin Liu, Ruiqing Peng(Sun Yat-sen University), Zhiyan Liang(East China University of Science and Technology), Shan Zeng(Central South University), Yang Chen(Kunming Medical University), Li Zhang(Shanghai Jiao Tong University), Xizhi Wen(Sun Yat-sen University), Yuxiang Ma(Sun Yat-sen University), Jiao Ji(Sun Yat-sen University), Yingjie Huang, Desheng Weng(Sun Yat-sen University), Yang Zhang(Capital University), Lichuang Men, Hengbang Wang
Cited by 8
Related Papers
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780
The measured electrical properties of normal and malignant human tissues from 50 to 900 MHz
|Medical Physics|1994|753
LIGHT, a TNF-Like Molecule, Costimulates T Cell Proliferation and Is Required for Dendritic Cell-Mediated Allogeneic T Cell Response
|The Journal of Immunology|2000|402
Understanding user behavior in online social networks: a survey
|IEEE Communications Magazine|2013|314